%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-05-16T12:59:30-04:00
2017-05-16T12:59:31-04:00
2017-05-16T12:59:31-04:00
Adobe InDesign CC 2017 (Windows)
uuid:820b6161-826a-4451-8f34-44e5a51d170d
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:cb524105-06d6-2240-9906-9b0146d27132
proof:pdf
xmp.iid:681b6082-91d8-434e-9ce9-35bdc699b9da
xmp.did:2662ab7f-1099-014d-bb3f-0d2ec036eacd
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2017-05-16T12:59:30-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
48 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
/CS0 CS 0.02 0.388 0.757 SCN
0.42 w
/GS0 gs
q 1 0 0 1 27.8983 45.5764 cm
0 0 m
76.046 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
7 0 0 7 27.8983 78.3659 Tm
(Interested in reprints or posting an article to your )Tj
0 -1.143 TD
[(company)-55.8 (\222s site? There are numerous opportunities for )]TJ
0 -1.143 TD
(you to leverage editorial recognition for the benefit of )Tj
0 -1.143 TD
(your brand. Call us at \(800\) 688-2421 or email us at )Tj
T*
[(R)17.6 (eprints@AHCMedia.com)]TJ
10.864 0 Td
(.)Tj
ET
/GS0 gs
q 1 0 0 1 211.467 53.5764 cm
0 0 m
73.773 0 l
S
Q
BT
/GS1 gs
7 0 0 7 204.4192 78.3659 Tm
(Discounts are available for group subscriptions, multiple )Tj
T*
(copies, site-licenses, or electronic distribution. For pricing )Tj
0 -1.143 TD
(information, please contact our Group Account Managers )Tj
0 -1.143 TD
(at )Tj
(Groups@AHCMedia.com)Tj
( or \(866\) 213-0844.)Tj
19.48 0 Td
( )Tj
/TT1 1 Tf
-19.48 -1.143 Td
( )Tj
ET
/GS0 gs
q 1 0 0 1 399.5885 53.5764 cm
0 0 m
60.303 0 l
S
Q
BT
/GS1 gs
/TT0 1 Tf
-0.006 Tw 7 0 0 7 380.94 78.3659 Tm
[(T)175 (o reproduce any part of AHC newsletters )1 (for educational )]TJ
0 Tw T*
(purposes, please contact:)Tj
0 -1.143 TD
(The Copyright Clearance Center for permission)Tj
/TT1 1 Tf
0 -1.143 TD
(Email: )Tj
/TT0 1 Tf
(Info@Copyright.com)Tj
/TT1 1 Tf
T*
(Phone: \(978\) 750-8400)Tj
ET
q
0 g
0 G
1 w
/GS0 gs
0 TL/Fm1 Do
Q
0.316 w
/GS0 gs
q 1 0 0 1 212.6432 673.4309 cm
0 0 m
55.355 0 l
S
Q
q 1 0 0 1 313.5374 673.4309 cm
0 0 m
40.413 0 l
S
Q
BT
/GS1 gs
/TT2 1 Tf
-0.01 Tc 9 0 0 9 171.2281 707.446 Tm
[(T)174.8 (o earn credit for this activity)87 (, please follow these instructions:)]TJ
0 Tc 0 -1.222 TD
( )Tj
-0.01 Tc T*
[(1. R)17.6 (ead and study the activity)87.1 (, using the provided references for further research.)-9.9 ( )]TJ
0 Tc 30.179 0 Td
( )Tj
-0.01 Tc -30.179 -1.222 Td
[(2. L)17.5 (og onto )]TJ
0.01 Tw (AHCMedia.com)Tj
0 Tw (, then select \223)Tj
(My Account)Tj
(\224 to take a post-test. )Tj
/TT3 1 Tf
[(F)35.5 (irst-time users must register on the)-10 ( )]TJ
0.01 Tw T*
(site.)Tj
0 Tc 0 Tw 1.463 0 Td
( )Tj
/TT2 1 Tf
-0.01 Tc -1.463 -1.222 Td
[(3. P)54.8 (ass the online tests with a score of 100%; you will be allowed to answer\
the questions as many times as)-10.2 ( )]TJ
T*
[(needed to achieve a score of 100%.)-9.9 ( )]TJ
0 Tc 13.831 0 Td
( )Tj
-0.01 Tc -13.831 -1.222 Td
[(4. After completing the test, a credit letter will be emailed to you ins\
tantly)87.1 (.)]TJ
T*
[(5. T)155.7 (wice yearly after the test, your browser will be directed to an activity\
evaluation form, which must be)-10 ( )]TJ
T*
[(completed to receive your credit letter)100.6 (.)]TJ
ET
q
0 Tc 0 g
0 G
1 w
/GS0 gs
0 TL/Fm2 Do
Q
endstream
endobj
51 0 obj
<>/ExtGState<>>>/Subtype/Form>>stream
/CS0 cs 0.07 scn
/GS0 gs
18 183.88 120.33 572.12 re
f
18 36 539.325 53.473 re
f
endstream
endobj
52 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 CS 1 SCN
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 138.6633 754.5 cm
0 0 m
437.337 0 l
S
Q
/CS0 cs 1 scn
163.325 236.08 392.623 17.367 re
f
BT
0 scn
/TT0 1 Tf
0.041 Tc -0.016 Tw 0 Ts 100 Tz 0 Tr 10 0 0 10 325.9038 242.3945 Tm
[(CM)1 (E)16 ( O)4.1 (B)11.9 (J)2.4 (E)24.3 (C)-1.4 (T)14.1 (I)0.5 (VE)9.9 (S)]TJ
ET
1 scn
163.328 561.32 392.414 17.367 re
f
BT
/T1_0 1 Tf
-0.01 Tc 0 Tw 8.5 0 0 8.5 171.3531 547.7129 Tm
[(1. In the study by Dietz and colleagues of patients)-10 ( )]TJ
-0.002 Tw 1.588 -1.2 Td
(who died or transitioned to hospice after a 30-)Tj
0 Tw 0 -1.2 TD
[(day readmission, what was the most common)-10 ( )]TJ
T*
[(cause of the readmission for patients admitted)-10 ( )]TJ
T*
(with sepsis during their index hospitalization?)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc 0 -1.729 TD
(a. Acute respiratory failure)Tj
T*
(b. Acute kidney injury requiring dialysis)Tj
0 -1.729 TD
[(c. Cerebrovascular accident \(CV)105 (A, stroke\))]TJ
0 -1.729 TD
(d. Infection)Tj
T*
(e. Failure to thrive)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc -1.588 -2.929 Td
[(2. In the observational study by Dingle, et al.,)-10 ( )]TJ
1.588 -1.2 Td
(a reduction in rates of )Tj
/T1_2 1 Tf
(Clostridium dif\037cile)Tj
/T1_0 1 Tf
0 Tc 18.256 0 Td
( )Tj
-0.01 Tc -18.256 -1.2 Td
[(infections seen in England after 2007 were)-10 ( )]TJ
0 -1.2 TD
(most likely due to:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc 0 -1.729 TD
(a. Spontaneous decrease in )Tj
/T1_3 1 Tf
(C. dif\037cile)Tj
/T1_1 1 Tf
( )Tj
-0 -1.2 Td
(colonization of high-risk patients )Tj
0 -1.729 TD
(b. Decreased use of \037uoroquinolones)Tj
0 -1.729 TD
(c. Improved use of isolation and hand-)Tj
0 -1.2 TD
(washing techniques)Tj
0 -1.729 TD
(d. Decreased use of third-generation )Tj
0 -1.2 TD
(cephalosporins)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 21.05 30.494 Td
[(3. Felker and co-investigators conducted a)-10 ( )]TJ
1.588 -1.2 Td
[(prospective, randomized, placebo-controlled)-10 ( )]TJ
T*
[(trial of tolvaptan in addition to furosemide in)-10 ( )]TJ
T*
[(patients admitted to the hospital with acute)-10 ( )]TJ
T*
(heart failure. The results of the study showed:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc 0 -1.729 TD
(a. No difference in the relief of dyspnea )Tj
0 -1.2 TD
(between tolvaptan and placebo)Tj
0 -1.729 TD
(b. Signi\036cantly greater weight and \037uid loss )Tj
0 -1.2 TD
(in the tolvaptan group compared to placebo)Tj
0 -1.729 TD
[(c. T)98 (olvaptan was associated with an )]TJ
0 -1.2 TD
(increased incidence of worsening renal )Tj
T*
(function compared to placebo)Tj
0 -1.729 TD
(d. All of the above)Tj
/CS0 cs 0 scn
/GS0 gs
/TT0 1 Tf
0.037 Tc -0.012 Tw 10 0 0 10 324.7854 566.9352 Tm
[(C)-3.7 (M)-3 (E)12 ( Q)1.9 (U)-3.3 (E)5.9 (S)4.8 (T)10.1 (ION)-11.3 (S)]TJ
ET
0.07 scn
163.266 596.16 392.475 128.72 re
f
endstream
endobj
53 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 cs 1 scn
/GS0 gs
163.412 724.88 392.33 17.367 re
f
BT
0 scn
/TT0 1 Tf
0.037 Tc -0.012 Tw 0 Ts 100 Tz 0 Tr 10 0 0 10 316.4674 730.4957 Tm
[(C)-3.7 (M)-3 (E)12 ( I)-1.3 (N)-11.4 (S)4.8 (T)7.7 (R)6.1 (U)2.7 (C)-5.3 (T)10.1 (ION)-11.3 (S)]TJ
1 scn
0.01 Tc 0 Tw 9 0 0 9 172.6092 224.2306 Tm
[(Upon completion of this educational activity)87.1 (, participants should be able to:)]TJ
ET
18 90 539.325 76.635 re
f
BT
0 0 0 0 k
/T1_0 1 Tf
0.057 Tc -0.032 Tw 18 0 0 18 29.3567 143.4534 Tm
[([)8.9 (I)-2.2 (N)32 ( FU)-7.2 (T)-9.2 (UR)0.5 (E)57 ( )]TJ
0 Tc 0 Tw 6.562 0 Td
( )Tj
0.013 Tc -0.013 Tw -6.562 -1.2 Td
[(I)-21.9 (S)-23.9 (S)-14.3 (U)-46.2 (E)-36.6 (S])]TJ
/TT0 1 Tf
0 Tc 0 Tw 3.719 0 Td
( )Tj
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
8 0 0 8 29.3567 735.0712 Tm
(EDITOR)Tj
/TT1 1 Tf
0 -1.375 TD
(Jill Drachenberg)Tj
/T1_0 1 Tf
0 -3 TD
(EDITOR)Tj
/TT1 1 Tf
0 -1.375 TD
(Dana Spector)Tj
/T1_0 1 Tf
0 -3 TD
(AHC )Tj
(EDITORIAL GROUP )Tj
0 -1.375 TD
(MANAGER)Tj
/TT1 1 Tf
T*
[(T)149.9 (er)9.8 (r)20 (e)15.1 (y L.)99.8 ( Hatcher)]TJ
/T1_0 1 Tf
0 -3 TD
(SENIOR )Tj
0 -1.375 TD
[(ACCREDIT)74.1 (A)74 (TIONS )]TJ
T*
(OFFICER)Tj
/TT1 1 Tf
T*
(Lee Landenberger)Tj
/T1_0 1 Tf
0 -3 TD
(EDITOR )Tj
/TT1 1 Tf
0 -1.375 TD
[(K)60.3 (enneth Steinberg,)100 ( MD)]TJ
T*
[(Pr)25.1 (of)10.1 (essor of Medicine)-18.8 (,)99.9 ( )]TJ
( )Tj
T*
[(Pr)25.1 (ogram Dir)20.7 (ector)100.4 (,)99.8 ( )]TJ
( )Tj
T*
(Internal Medicine Residency )Tj
T*
[(Pr)25.1 (ogram,)100.6 ( )]TJ
( )Tj
-0.125 Tw T*
[(Univ)19.8 (ersity )-124.9 (of )0.5 (W)60 (ashington)]TJ
/T1_0 1 Tf
0 Tw 0 -3 TD
(PEER REVIEWER )Tj
/TT1 1 Tf
0 -1.375 TD
[(Rachael Safyan,)100.8 ( MD)]TJ
T*
[(Hematolog)-19.3 (y/Oncolog)-19.5 (y F)15.1 (ello)9.5 (w)59.8 (,)99.9 ( )]TJ
( )Tj
T*
[(Columbia Univ)20 (ersity Medical )]TJ
T*
(Center)Tj
/T1_0 1 Tf
0 -3 TD
[(ADVISOR)92.1 (Y BOARD )]TJ
/TT1 1 Tf
-0.125 Tw 0 -1.375 TD
[(K)60.3 (e)15.1 (vin T)149.9 (ompkins,)100.1 ( )-124.9 (MD)]TJ
0 Tw T*
[(P)25.1 (ediatric Hospitalist)]TJ
T*
[(Mer)25.1 (cy Childr)20 (en\222)79.8 (s Hospital-St.)100.3 ( )]TJ
T*
(Louis)Tj
/CS0 cs 1 scn
/GS0 gs
/TT2 1 Tf
0.01 Tc 9 0 0 9 171.4781 209.151 Tm
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
[(discuss pertinent safety)87.1 (, infection control and quality improvement practices;)]TJ
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(explain diagnosis and treatment of acute illness in the hospital setting\
; and;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
[(discuss current data on diagnostic and therapeutic modalities for common\
inpatient problems.)10.1 ( )]TJ
0 0 0 0 k
/TT3 1 Tf
0 Tc -3.33 -6.684 Td
[(More original, peer)21 (-reviewed content by and for hospitalists)]TJ
ET
/CS0 CS 1 SCN
1 w 4 M 0 j 0 J
163.766 266.9 391.62 293.92 re
S
163.766 184.38 391.62 51.199 re
S
endstream
endobj
59 0 obj
<>
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
62 0 obj
<>
endobj
63 0 obj
<>
endobj
72 0 obj
<>
endobj
73 0 obj
<>stream
H\n0y
CBh+q؏ 41Q~6:i_8|؉Xn= ـpΩM3}MxQr=k}8pނй+<}
&(bK4%m]YZyM9;>g,ȘqWTyLLPd+i|7A oc
ĥp|>)sYq"0o̩pʼ1g{=A,>d'Y~0_f->}hAf-ߥEWG]Go-jr~p':ŏ` |D
endstream
endobj
74 0 obj
<>stream
H|y\TGz̛x$ϸIuݸDQ#/ThDToV>fDu\5Ə9fGҟOUwuuWw?5?F@F\uet$zBz$'fvl3X TJe6&KjM̞5; iCR?M9_hWJbOfSDƽDGp%^Y"we$%Ro[ QzbvfxF)ƛ%-? 10
b=)L n@$T^LE\T)IbY1(ldwQcf4]ZSCBۛn=YسB~E50^vZ